- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.06. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.06. | CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET | 2 | Investing.com | ||
| 28.05. | Elutia Inc.: Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method | 1 | GlobeNewswire (USA) | ||
| 13.05. | ELUTIA INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.05. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 01.05. | Elutia Inc.: Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | 77 | GlobeNewswire (Europe) | Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting... ► Artikel lesen | |
| 01.05. | Elutia Inc.: Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 | 1 | GlobeNewswire (USA) | ||
| 21.04. | Elutia Inc.: Elutia Initiates EluPro Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | 1 | GlobeNewswire (USA) | ||
| 04.04. | Elutia Inc.: EluPro Named as 2025 Edison Award Winner | 2 | GlobeNewswire (USA) | ||
| 27.03. | Elutia Inc.: Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro | 2 | GlobeNewswire (USA) | ||
| 25.03. | Elutia Inc.: Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope | 1 | GlobeNewswire (USA) | ||
| 17.03. | Elutia stock soars, Anteris falls in medical devices sector | 4 | Investing.com | ||
| 11.03. | ELUTIA INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Cantor Fitzgerald keeps Aziyo Biologics stock at $8 target | 1 | Investing.com | ||
| 07.03. | Cantor Fitzgerald maintains $8 target on Aziyo Biologics stock | 1 | Investing.com | ||
| 06.03. | Elutia Inc. Q4 Loss Decreases | - | RTTNews | ||
| 06.03. | Elutia Inc.: Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro in Pilot Launch Sets the Stage for Full Commercial Roll-Out | 78 | GlobeNewswire (Europe) | - Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization - SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"... ► Artikel lesen | |
| 06.03. | ELUTIA INC. - 8-K, Current Report | - | SEC Filings | ||
| 20.02. | Elutia Inc.: Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 03.02. | Elutia launches $15M securities offering | 3 | Seeking Alpha |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
Das Unternehmen ELUTIA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +20,69 % bei einem Aktienkurs von 2,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.